

## IRLAB: Invitation to the year-end report 2024 presentation and webcast

Gothenburg, Sweden, February 7, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that the company will hold a presentation in conjunction with the publication of the year-end report for 2024. The interim report will be published on Wednesday, February 12 at 07:00 CET.

The presentation will be held on February 12, 2025, at 10:00 CET via digital webcast. Kristina Torfgård, CEO, Nicholas Waters, EVP and Head of R&D, and Viktor Siewertz, CFO, will comment the year-end report. The presentation will be held in English and will be followed by a Q&A session.

Follow the webcast online: <https://www.youtube.com/watch?v=udzoDVqBbcM>

The year-end report and the presentation will be available on [www.irlab.se](http://www.irlab.se), and the recorded version of the presentation will be available shortly afterward.

### For more information

Kristina Torfgård, VD

Phone: +46 730 60 70 99

E-mail: [kristina.torfgard@irlab.se](mailto:kristina.torfgard@irlab.se)

Viktor Siewertz, CFO

Phone: +46 727 10 70 70

E-mail: [viktor.siewertz@irlab.se](mailto:viktor.siewertz@irlab.se)

Press Release

Göteborg February 7, 2025



## About IRLAB

IRLAB discovers and develops a portfolio of transformative treatments for all stages of Parkinson's disease. The company originates from Nobel Laureate Prof Arvid Carlsson's research group and the discovery of a link between brain neurotransmitter disorders and brain diseases. Mesdopetam (IRL790), under development for treating levodopa-induced dyskinesias, has completed Phase IIb and is in preparation for Phase III. Pirepemat (IRL752), currently in Phase IIb, is being evaluated for its effect on balance and fall frequency in Parkinson's disease. IRL757, a compound being developed for the treatment of apathy in neurodegenerative disorders, is in Phase I. In addition, the company is developing two preclinical programs, IRL942 and IRL1117, towards Phase I studies. IRLAB's pipeline has been generated by the company's proprietary systems biology-based research platform Integrative Screening Process (ISP). Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit [www.irlab.se](http://www.irlab.se).

## Attachments

[IRLAB: Invitation to the year-end report 2024 presentation and webcast](#)